Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6388213 | 0.91 | TSHR (0.59) | TSHRRAB9AAPEX1BLMSMN1; SMN2 | |
| SCHEMBL236431 | 0.77 | TSHR (0.56) | TSHRRAB9ASMN1; SMN2ALDH1A1ALOX12 | |
| SCHEMBL3785481 | 0.76 | POLB (0.58) | ALDH1A1CYP2C19LMNAKDM4E | |
| SCHEMBL9182492 | 0.76 | L3MBTL1 (0.43) | TSHRSMN1; SMN2ALDH1A1LMNAKMT2A | |
| SCHEMBL2719070 | 0.75 | ALDH1A1 (0.43) | TSHRRAB9ASMN1; SMN2ALDH1A1ALOX12 | |
| SCHEMBL5091798 | 0.75 | TSHR (0.44) | TSHRRAB9ASMN1; SMN2ALDH1A1ALOX12 | |
| SCHEMBL7773775 | 0.75 | SMN1; SMN2 (0.43) | TSHRRAB9ASMN1; SMN2ALDH1A1ALOX12 | |
| SCHEMBL8577573 | 0.75 | ALDH1A1 (0.46) | TSHRRAB9ASMN1; SMN2ALDH1A1ALOX12 | |
| SCHEMBL6037020 | 0.75 | SMN1; SMN2 (0.43) | TSHRRAB9ASMN1; SMN2ALDH1A1ALOX12 | |
| SCHEMBL23618003 | 0.75 | MAPT (0.46) | TSHRSMN1; SMN2ALDH1A1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3432934-B1 | PRODRUGS OF CYTOTOXIC AGENTS WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma AG (DE) | 2022-02-23 | — | — | EP | disclosed |
| WO-2021123506-A1 | STABILE CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2021-06-24 | — | — | WO | disclosed |
| US-20160193359-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | SEATTLE GENETICS, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| US-8992932-B2 | Binder-drug conjugates (ADCs) and use thereof | SEATTLE GENETICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150030618-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150023989-A1 | NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF | SEATTLE GENETICS, INC. | 2015-01-22 | — | — | US | disclosed |
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20130122024-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | Bayer Pharma AG (DE) | 2013-04-18 | — | — | US | disclosed |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130122024-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | MDN1, EPCAM, VCAM1 | TSHR 3764/4885RAB9A 3070/4885APEX1 1892/4885 |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | TSHR 3625/4885RAB9A 1941/4885APEX1 2086/4885 |
| US-20160193359-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | TSHR 3625/4885RAB9A 1941/4885APEX1 2086/4885 |
| US-20150023989-A1 | NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF | FGFR2, FGFR1, FGFR3 | TSHR 1307/4885RAB9A 2095/4885APEX1 3962/4885 |
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | DDR1, IGFBP6, KDR | TSHR 2495/4885RAB9A 2663/4885APEX1 3403/4885 |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | DDR1, IGFBP6, KDR | TSHR 2495/4885RAB9A 2663/4885APEX1 3403/4885 |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | CDK4, CDKL4, FLT4 | TSHR 3625/4885RAB9A 1941/4885APEX1 2086/4885 |
| US-20150030618-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | TSHR 3633/4885RAB9A 1848/4885APEX1 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.